abstract
Nocturnal hypoglycemia is a barrier to therapy intensification efforts in diabetes. The Paradigm(R) Veo system may mitigate nocturnal hypoglycemia by automatically suspending insulin when a prespecified sensor glucose threshold is reached. ASPIRE (Automation to Simulate Pancreatic Insulin REsponse) In-Home (NCT01497938) was a multicenter, randomized, parallel, adaptive study of subjects with type 1 diabetes. The control arm used sensor-augmented pump therapy. The treatment arm used sensor-augmented pump therapy with threshold suspend, which automatically suspends the insulin pump in response to a sensor glucose value at or below a prespecified threshold. To be randomized, subjects had to have demonstrated >/=2 episodes of nocturnal hypoglycemia, defined as >20 consecutive minutes of sensor glucose values
